Stocks and Investing
Stocks and Investing
Fri, February 2, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, February 1, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Edward Tenthoff Maintained (APTO) at Buy with Decreased Target to $5 on, Feb 1st, 2024
Edward Tenthoff of Piper Sandler, Maintained "Aptose Biosciences Inc." (APTO) at Buy with Decreased Target from $12 to $5 on, Feb 1st, 2024.
Edward has made no other calls on APTO in the last 4 months.
There is 1 other peer that has a rating on APTO. Out of the 1 peers that are also analyzing APTO, 0 agree with Edward's Rating of Hold.
This is the rating of the analyst that currently disagrees with Edward
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $18 on, Friday, November 10th, 2023
Contributing Sources